Although single-PPAR agonists like TZDs are effective, they are associated with several adverse effects such as edema, bone fractures, and heart failure, which largely restricts the extended use for the long-term management of T2D patients16–18. This evidence concerns the gene PPARA and type 2 diabetes mellitus.